title: MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma.
abstract: OBJECTIVE
  Mucoepidermoid carcinoma is the most common primary malignancy of the salivary gland. Mucoepidermoid carcinoma translocated gene 1-mastermind-like gene family (MECT1-MAML2) gene fusion was identified from a recurring t(11;19)(q21;p13) translocation, which is often the sole cytogenetic alteration in this disease. This fusion transcript has been frequently detected in mucoepidermoid carcinoma and shown to be involved in the transformation of epithelial cells. However, its clinicopathologic significance remains unclear.
  
  
  METHODS
  Seventy-one cases of mucoepidermoid carcinoma and 51 cases of nonmucoepidermoid carcinoma salivary gland tumors (including 26 Warthin tumor cases) were retrospectively analyzed. RNA was extracted from archival materials: histologic paraffin specimens in all cases and cytologic specimens in 10 mucoepidermoid carcinoma cases. The MECT1-MAML2 fusion transcript was detected by a reverse transcription-PCR assay, which can be applied to both histologic and cytologic specimens. The presence of the fusion transcript was correlated with relevant clinicopathologic and survival data of the mucoepidermoid carcinoma patients.
  
  
  RESULTS
  The MECT1-MAML2 fusion transcript was detected in 27 of the 71 (38%) mucoepidermoid carcinoma cases but not in any case of nonmucoepidermoid carcinoma tumors. The reverse transcription-PCR results showed no difference between histologic and cytologic specimens. Detection of the MECT1-MAML2 fusion transcript was associated with a less advanced clinical stage and a low-grade tumor histology. The presence of the transcript was associated with longer disease-free and overall survivals on univariate analysis and emerged as an independent prognostic factor for longer overall survival on multivariate analysis.
  
  
  CONCLUSIONS
  The MECT1-MAML2 fusion transcript may be specific to mucoepidermoid carcinoma and associated with a distinct mucoepidermoid carcinoma subset that exhibits favorable clinicopathologic features and an indolent clinical course.
authors.affiliation: Department of Pathology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
authors.forename: Mitsukuni
authors.initials: M
authors.lastname: Okabe
authors.forename: Satoru
authors.initials: S
authors.lastname: Miyabe
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nagatsuka
authors.forename: Akihiro
authors.initials: A
authors.lastname: Terada
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Hanai
authors.forename: Motoo
authors.initials: M
authors.lastname: Yokoi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shimozato
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Eimoto
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Nagai
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Hasegawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Inagaki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018277:Carcinoma, Mucoepidermoid / Q000145:classification / Q000235:genetics* / Q000473:pathology; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D012468:Salivary Gland Neoplasms / Q000145:classification / Q000235:genetics* / Q000473:pathology; D015996:Survival Rate; D014158:Transcription, Genetic / Q000235:genetics*
chemical_list: C495418:MECT1-MAML2 fusion protein, human; D015514:Oncogene Proteins, Fusion